Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus SODIUM PERTECHNETATE TC 99M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus SODIUM PERTECHNETATE TC 99M.
MPI INDIUM DTPA IN 111 vs SODIUM PERTECHNETATE TC 99M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Sodium pertechnetate Tc-99m is a radiopharmaceutical that emits gamma rays (140 keV). The pertechnetate anion (TcO4−) is taken up by the thyroid gland via the sodium-iodide symporter (NIS) and also distributes in salivary glands, gastric mucosa, and choroid plexus. It acts as a diagnostic imaging agent by localizing in tissues via active transport or diffusion, allowing external detection with gamma cameras.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
370-1110 MBq (10-30 mCi) intravenously as a single dose for brain imaging; 370-740 MBq (10-20 mCi) intravenously for thyroid imaging; 185-370 MBq (5-10 mCi) intravenously for salivary gland imaging.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: approximately 6 hours. Clinical context: Allows for imaging up to several hours post-injection; clearance is delayed in renal impairment.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: approximately 30-50% of the injected dose is excreted in urine within 24 hours. The remainder is eliminated via the hepatobiliary system into feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical